Tiny, biodegradable particles filled with medicine may also contain answers to some of the biggest human health problems, including cancer and tuberculosis. The secret is the size of the package.
Pharmaceutical Research and Manufacturers of America Senior Vice President Ken Johnson issued the following statement on the AARP?s campaign to modify the Medicare prescription drug program:
Kamal Motiram Vidhani, a resident of suburban Khar, slapped a legal notice on Wockhardt last month after he failed to receive suitable compensation from the pharmaceutical firm.
Cephalon, Inc. (Nasdaq: CEPH) announced that it has received an approvable letter, together with draft labeling, from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for NUVIGIL(TM) (armodafinil) Tablets [C-IV] for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift work sleep disorder (SWSD).
Cell Genesys, Inc. (Nasdaq: CEGE) announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic hormone-refractory prostate cancer (HRPC).
Treatment of mice with a ?friendly? bacteria, normally found in the soil, altered their behavior in a way similar to that produced by antidepressant drugs, reports research published in the latest issue of Neuroscience.
Pharmaceutical manufacturers and their trade groups spent a record $155 million lobbying the federal government and its agencies from January 2005 to June 2006, according to a Center for Public Integrity report based on data obtained from the Senate Office of Public Records.
GlaxoSmithKline K.K. (Head Office: Shibuya-ku, Tokyo, President: Marc Dunoyer, hereinafter referred to as GSK) announced the submission of a New Drug Application (NDA) to the Japanese authorities for approval to market lapatinib, its new cancer drug on 30 March.
Treatment of mice with a ?friendly? bacteria, normally found in the soil, altered their behavior in a way similar to that produced by antidepressant drugs, reports research published in the latest issue of Neuroscience.
With a newly discovered method of assembling organic molecules, a team of Princeton University chemists may have found a way to sidestep many of the expensive and hazardous barriers that stand in the way of drug development.